Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma, has received approval from the U.S. Federal Trade Commission (FTC) to acquire Lannett Company LLC. The transaction is valued at $250 million on a cash-free, debt-free basis and includes normalized working capital. The deal is expected to close before the end of June 2026.

Transaction Details

The acquisition involves purchasing 100% of the membership interest in Lannett Company LLC. Lannett is a Pennsylvania-based generic pharmaceutical company specializing in complex, non-opioid controlled substances. The following table outlines the key entities involved in the deal:

Strategic Benefits

The acquisition will add a U.S.-based manufacturing facility in Seymour, Indiana, to Aurobindo USA's network. This site has the capacity to scale production to approximately 4 billion doses annually. The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share and generate cost efficiencies and SG&A synergies.

Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, stated that the acquisition accelerates revenue growth and strengthens U.S.-based manufacturing capabilities. Tim Crew, Chief Executive Officer of Lannett Company, expressed confidence that Aurobindo's market reach will make their portfolio of medicines more affordable and accessible.

Aurobindo Pharma 's Eugia Unit-III facility has received an Official Action Indicated (OAI) classification from the United States Food and Drug Administration (US FDA) following a regulatory inspection that recorded 11 findings at the site. The development has drawn divergent responses from global brokerages, with Bernstein flagging near-term earnings risks while HSBC maintains a more constructive stance on the company's outlook, underpinned by strategic growth catalysts including the Lannett acquisition and an anticipated gAdvair launch.

OAI Classification and Inspection Findings

The OAI status is one of the more serious designations issued by the US FDA following facility inspections. It signals that the agency has identified conditions or practices at the inspected site that warrant official regulatory or administrative action. The inspection of Eugia Unit-III resulted in a total of 11 findings, underscoring the scope of the agency's observations at the facility.

Key details of the development are outlined below:

Bernstein's Assessment and Earnings Impact

Bernstein has maintained its Market Perform rating on Aurobindo Pharma with a target price of ₹1,498, while flagging meaningful near-term risks stemming from the OAI designation. According to the brokerage, while the OAI classification does not immediately halt shipments from the facility, it carries significant operational and financial consequences. Bernstein estimates the OAI could freeze approximately 35 pending Abbreviated New Drug Applications (ANDAs), limiting Aurobindo Pharma's near-term product launch pipeline from the affected site.

The financial impact, as assessed by Bernstein, is summarised below:

Bernstein's commentary also draws attention to the site's repeated OAI and warning-letter history, which the brokerage views as indicative of ongoing quality execution concerns at the facility. Despite acknowledging Aurobindo Pharma's long-term capability strengthening efforts, the brokerage underscores that the recurrence of regulatory observations at this unit remains a point of concern for investors and stakeholders tracking the company's compliance track record.

HSBC's View: Lannett Acquisition and Growth Catalysts

In contrast, HSBC has maintained a Buy rating on Aurobindo Pharma with a target price of ₹1,580. The brokerage notes that while the FDA OAI classification for Eugia Unit-III may delay compliance resolution, it does not imply any incremental business impact for the company. HSBC's constructive outlook is further supported by strategic growth drivers, with the Lannett acquisition expected to drive the US business closer to USD 2 billion in sales by FY27. Additionally, the launch of gAdvair is identified as a key near-term catalyst for the company. HSBC also highlights cost breakeven in the Pen G and China plants as supporting earnings visibility.

A comparison of the two brokerage views is presented below:

An OAI designation from the US FDA typically precedes formal regulatory actions, which may include warning letters, import alerts, or other enforcement measures, depending on the nature and severity of the findings. Aurobindo Pharma has not yet issued a public statement regarding the specific nature of the 11 findings or its planned response to the OAI classification, based on information currently available.